Get the Stockscreener App
13.59
1.12%
0.15
Angiodynamic Inc stock is traded at $13.59, with a volume of 333.00K.
It is up +1.12% in the last 24 hours and up +4.94% over the past month.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
See More
Previous Close:
$13.44
Open:
$13.56
24h Volume:
333.00K
Relative Volume:
0.86
Market Cap:
$561.71M
Revenue:
$320.17M
Net Income/Loss:
$-36.74M
P/E Ratio:
-15.35
EPS:
-0.8856
Net Cash Flow:
$-2.86M
1W Performance:
+0.59%
1M Performance:
+4.94%
6M Performance:
+30.92%
1Y Performance:
+49.18%
1-Day Range:
$13.42
$13.76
1-Week Range:
$13.22
$14.36
52-Week Range:
$8.36
$15.20
Angiodynamic Inc Stock (ANGO) Company Profile
Name
Angiodynamic Inc
Sector
Industry
Phone
(518) 798-1215
Address
14 PLAZA DRIVE, LATHAM
Compare ANGO vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANGO
Angiodynamic Inc
|
13.59 | 561.71M | 320.17M | -36.74M | -2.86M | -0.8856 |
ISRG
Intuitive Surgical Inc
|
337.50 | 120.92B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
156.36 | 43.08B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.91 | 33.12B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
38.75 | 32.77B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
195.27 | 28.33B | 5.54B | 1.52B | 1.74B | 10.37 |
Angiodynamic Inc Stock (ANGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-25 | Initiated | Lake Street | Buy |
| Apr-05-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-25-23 | Initiated | H.C. Wainwright | Buy |
| Apr-17-23 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-15-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-20-21 | Initiated | Oppenheimer | Perform |
| Nov-25-20 | Upgrade | Raymond James | Mkt Perform → Strong Buy |
| Apr-08-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-01-19 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Apr-03-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-18 | Downgrade | Craig Hallum | Buy → Hold |
| Apr-07-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Mar-30-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
| Feb-08-17 | Initiated | Barclays | Equal Weight |
| Nov-04-16 | Initiated | Cantor Fitzgerald | Buy |
| Apr-08-16 | Resumed | Piper Jaffray | Neutral |
| Jan-08-16 | Reiterated | Canaccord Genuity | Buy |
| Nov-10-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-24-15 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jun-19-14 | Upgrade | Canaccord Genuity | Hold → Buy |
| Oct-09-12 | Reiterated | Canaccord Genuity | Hold |
| Jun-25-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-15-11 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-15-11 | Upgrade | Stifel Nicolaus | Hold → Buy |
| Jun-14-11 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-08-10 | Reiterated | Wedbush | Neutral |
View All
Angiodynamic Inc Stock (ANGO) Latest News
Form 4 AngioDynamics Inc For: 22 July By Investing.com - Investing.com Canada
AngioDynamics (ANGO) director receives 11,887-share stock award - Stock Titan
AngioDynamics Inc (ANGO) director awarded 11,887 shares in annual grant - Stock Titan
ETFs Investing in AngioDynamics, Inc. Stocks - TradingView
AngioDynamics (ANGO) CFO withholds 12,067 shares to satisfy RSU tax obligations - Stock Titan
AngioDynamics (ANGO) SVP reports 3,838-share tax withholding event - Stock Titan
AngioDynamics: NanoKnife Momentum Looks Real, But Much Of The Good News Is Priced In - Seeking Alpha
AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade) - Seeking Alpha
AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands - TradingView
AngioDynamics (NASDAQ: ANGO) details device portfolio and risk factors - Stock Titan
ANGIODYNAMICS INC FY 2026: Revenue $320.17M, EPS ($0.88) — 10-K Summary - TradingView
Is AngioDynamics Inc (ANGO) Overvalued After Q4 Earnings Miss? E - GuruFocus
AngioDynamics Inc reports results for the quarter ended May 31Earnings Summary - TradingView
AngioDynamics, Inc. 2026 Q4ResultsEarnings Call Presentation (NASDAQ:ANGO) 2026-07-14 - Seeking Alpha
AngioDynamics Releases Q4 2026 Financial Results - AlphaStreet
Record 2026 sales as AngioDynamics (NASDAQ: ANGO) grows Med Tech 18% - Stock Titan
AngioDynamics: Fiscal Q4 Earnings Snapshot - KVUE
AngioDynamics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Enterprise value to revenue forward of AngioDynamics, Inc. – NASDAQ:ANGO - TradingView
Price to earnings forward of AngioDynamics, Inc. – NASDAQ:ANGO - TradingView
Enterprise value to EBIT forward of AngioDynamics, Inc. – NASDAQ:ANGO - TradingView
ANGOAngiodynamic Inc Latest SEC Filings - Finviz
Price to sales forward of AngioDynamics, Inc. – NASDAQ:ANGO - TradingView
Price to sales forward of AngioDynamics, Inc. – LS:A0B9A5 - TradingView
Press Release: AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026 - Moomoo
AngioDynamics sets July 14 call for fiscal 2026 results - Stock Titan
AngioDynamics, Inc.(NasdaqGS: ANGO) added to Russell 2000 Value-Defensive Index - marketscreener.com
AngioDynamics, Inc. Actuals & Estimates (NASDAQ:ANGO) - TradingView
ANGO Forecast — Price Target — Prediction for 2027 - TradingView
AngioDynamics Inc. (ANGO) Rises 5.25%: Support and Resistance Levels in FocusInitial Balance - dars.gov.et
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now - TradingView
AngioDynamics Inc (ANGO) Valuation: PE, PB & Fair Value Analysis - TradingKey
AngioDynamics Inc (ANGO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AngioDynamics wins FDA okay to test NanoKnife in BPH patients - Stock Titan
AngioDynamics Inc (ANGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AngioDynamics Inc (ANGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AngioDynamics Inc (ANGO) Institutional Confidence - TradingKey
AngioDynamics Inc (ANGO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026Slideshow - Seeking Alpha
ANGO News | ANGIODYNAMICS INC (NASDAQ:ANGO) - ChartMill
Port Catheter Thrombosis Lawsuit Claims Defective AngioDynamics Xcela Device Caused Injury - AboutLawsuits.com
ANGO Technical Analysis & Stock Price Forecast - Intellectia AI
ANGO Stock Price, Quote & Chart | ANGIODYNAMICS INC (NASDAQ:ANGO) - ChartMill
Webcast set for AngioDynamics talk at Goldman Sachs health event - Stock Titan
Reasons to Add AngioDynamics Stock to Your Portfolio for Now - Yahoo Finance
Point72 (ANGO) reports 3.18M shares, 7.7% stake via Point72 Associates - Stock Titan
Prostate cancer trial sees 0 new failures with NanoKnife at 2 years - Stock Titan
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet - Yahoo Finance
AngioDynamics alleges patent infringement by E2 over clot removal technology - MassDevice
[8-K] ANGIODYNAMICS INC Reports Material Event - Stock Titan
Fair Value Assessment | AngioDynamics Inc. posts 117.8% EPS surprise beating loss estimatesEarnings Risk - Cổng thông tin điện tử tỉnh Tây Ninh
Angiodynamic Inc Stock (ANGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Angiodynamic Inc Stock (ANGO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nighan Warren JR | SVP Quality and Regulatory |
Jul 22 '26 |
Option Exercise |
0.00 |
5,694 |
0 |
89,786 |
| Trowbridge Stephen A | EVP and CFO |
Jul 22 '26 |
Option Exercise |
0.00 |
16,296 |
0 |
314,115 |
| Clemmer James C | President and CEO |
Jul 22 '26 |
Option Exercise |
0.00 |
52,358 |
0 |
889,176 |
| Campbell Chad Thomas | SVP/GM, Vascular Access |
Jul 22 '26 |
Option Exercise |
0.00 |
6,466 |
0 |
111,006 |
| Weiss Lawrence T | SVP, Chief Legal Officer |
Oct 21 '25 |
Buy |
11.81 |
10,000 |
118,100 |
93,597 |
| Trowbridge Stephen A | EVP and CFO |
Oct 13 '25 |
Buy |
11.16 |
890 |
9,932 |
256,629 |
| Clemmer James C | President and CEO |
Oct 09 '25 |
Buy |
11.15 |
10,000 |
111,500 |
882,529 |
3.37%
0.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):